Display options
Cite
Bedi S, Garcia E, Jeyarajah EJ, et al. Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay. J Clin Med. 2020;9(9)doi: 10.3390/jcm9092915.
Bedi, S., Garcia, E., Jeyarajah, E. J., Shalaurova, I., Perez-Matos, M. C., Jiang, Z. G., Dullaart, R. P. F., Matyus, S. P., Kirk, W. J., Otvos, J. D., Davidson, W. S., & Connelly, M. A. (2020). Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay. Journal of clinical medicine, 9(9), . https://doi.org/10.3390/jcm9092915
Bedi, Shimpi, et al. "Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay." Journal of clinical medicine vol. 9,9 (2020). doi: https://doi.org/10.3390/jcm9092915
Bedi S, Garcia E, Jeyarajah EJ, Shalaurova I, Perez-Matos MC, Jiang ZG, Dullaart RPF, Matyus SP, Kirk WJ, Otvos JD, Davidson WS, Connelly MA. Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay. J Clin Med. 2020 Sep 10;9(9). doi: 10.3390/jcm9092915. PMID: 32927635; PMCID: PMC7564541.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2020 Sep 10;9(9). doi: 10.3390/jcm9092915.

Characterization of LP-Z Lipoprotein Particles and Quantification in Subjects with Liver Disease Using a Newly Developed NMR-Based Assay.

Journal of clinical medicine

Shimpi Bedi, Erwin Garcia, Elias J Jeyarajah, Irina Shalaurova, Maria Camila Perez-Matos, Z Gordon Jiang, Robin P F Dullaart, Steven P Matyus, William J Kirk, James D Otvos, W Sean Davidson, Margery A Connelly

Affiliations

  1. Center for Lipid and Arteriosclerosis Science, Department of Pathology and Laboratory Medicine, University of Cincinnati, Cincinnati, OH 45237-0507, USA.
  2. Laboratory Corporation of America Holdings (LabCorp), Burlington, NC 27560, USA.
  3. Division of Gastroenterology & Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
  4. Department of Endocrinology, University of Groningen, University Medical Center Groningen, 9713 Groningen, The Netherlands.

PMID: 32927635 PMCID: PMC7564541 DOI: 10.3390/jcm9092915

Abstract

BACKGROUND: Lipoprotein particles with abnormal compositions, such as lipoprotein X (LP-X) and lipoprotein Z (LP-Z), have been described in cases of obstructive jaundice and cholestasis. The study objectives were to: (1) develop an NMR-based assay for quantification of plasma/serum LP-Z particles, (2) evaluate the assay performance, (3) isolate LP-Z particles and characterize them by lipidomic and proteomic analysis, and (4) quantify LP-Z in subjects with various liver diseases.

METHODS: Assay performance was assessed for linearity, sensitivity, and precision. Mass spectroscopy was used to characterize the protein and lipid content of isolated LP-Z particles.

RESULTS: The assay showed good linearity and precision (2.5-6.3%). Lipid analyses revealed that LP-Z particles exhibit lower cholesteryl esters and higher free cholesterol, bile acids, acylcarnitines, diacylglycerides, dihexosylceramides, lysophosphatidylcholines, phosphatidylcholines, triacylglycerides, and fatty acids than low-density lipoprotein (LDL) particles. A proteomic analysis revealed that LP-Z have one copy of apolipoprotein B per particle such as LDL, but less apolipoprotein (apo)A-I, apoC3, apoA-IV and apoC2 and more complement C3. LP-Z were not detected in healthy volunteers or subjects with primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis, or type 2 diabetes. LP-Z were detected in some, but not all, subjects with hypertriglyceridemia, and were high in some subjects with alcoholic liver disease.

CONCLUSIONS: LP-Z differ significantly in their lipid and protein content from LDL. Further studies are needed to fully understand the pathophysiological reason for the enhanced presence of LP-Z particles in patients with cholestasis and alcoholic liver disease.

Keywords: cholestasis; lipoproteins; liver disease; nuclear magnetic resonance spectroscopy

References

  1. Nat Rev Gastroenterol Hepatol. 2014 Jan;11(1):55-67 - PubMed
  2. Biochim Biophys Acta. 2016 Jul;1861(7):630-8 - PubMed
  3. Biochem J. 1976 Aug 1;157(2):401-7 - PubMed
  4. Oxid Med Cell Longev. 2013;2013:385214 - PubMed
  5. Gastroenterology. 1977 Mar;72(3):510-8 - PubMed
  6. Phys Rev Lett. 1994 Jun 20;72(25):4049-4052 - PubMed
  7. Clin Sci Mol Med. 1978 Apr;54(4):369-79 - PubMed
  8. Ann Clin Biochem. 2013 Mar;50(Pt 2):173-5 - PubMed
  9. J Lipid Res. 2017 Jul;58(7):1374-1385 - PubMed
  10. Ann Clin Lab Sci. 1984 Sep-Oct;14(5):371-4 - PubMed
  11. J Clin Invest. 1970 Dec;49(12):2396-407 - PubMed
  12. J Proteomics. 2014 Jun 25;106:181-90 - PubMed
  13. Gut. 1973 Jun;14(6):451-6 - PubMed
  14. J Endocr Soc. 2019 Jun 10;3(8):1503-1517 - PubMed
  15. J Clin Invest. 2002 Apr;109(7):961-71 - PubMed
  16. J Lipid Res. 1982 May;23(4):556-69 - PubMed
  17. BMJ. 2018 Jul 18;362:k2817 - PubMed
  18. Gastroenterology. 2003 Aug;125(2):544-55 - PubMed
  19. Pediatr Res. 2019 Sep;86(3):375-381 - PubMed
  20. Curr Opin Lipidol. 2019 Feb;30(1):30-36 - PubMed
  21. Clin Biochem. 2015 Feb;48(3):148-55 - PubMed
  22. Gut. 1970 Dec;11(12):1035-7 - PubMed
  23. Clin Chim Acta. 2010 Mar;411(5-6):336-44 - PubMed
  24. Clin Biochem. 2015 Aug;48(12):811-4 - PubMed
  25. Biochim Biophys Acta. 2016 Aug;1861(8 Pt A):681-7 - PubMed
  26. Scand J Clin Lab Invest Suppl. 1978;150:223-7 - PubMed
  27. J Clin Invest. 1969 Jul;48(7):1211-23 - PubMed
  28. Proc Natl Acad Sci U S A. 1977 Nov;74(11):5150-4 - PubMed
  29. Eur J Clin Invest. 2018 Sep;48(9):e12988 - PubMed
  30. Arterioscler Thromb Vasc Biol. 2018 Dec;38(12):2827-2842 - PubMed
  31. Cell Metab. 2013 May 7;17(5):657-69 - PubMed
  32. Clin Biochem. 2014 Nov;47(16-17):203-10 - PubMed
  33. Clin Lab Med. 2006 Dec;26(4):847-70 - PubMed
  34. J Clin Lipidol. 2017 Jan - Feb;11(1):282-286 - PubMed
  35. J Biol Chem. 2005 Mar 4;280(9):7427-34 - PubMed
  36. Baillieres Clin Endocrinol Metab. 1990 Dec;4(4):807-32 - PubMed

Publication Types

Grant support